John F. Paolini - 07 Dec 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
07 Dec 2023
Net transactions value
-$451,562
Form type
4
Filing time
11 Dec 2023, 16:20:06 UTC
Previous filing
06 Sep 2023
Next filing
29 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $53,196 +28,600 +64% $1.86* 73,492 07 Dec 2023 Direct F1
transaction KNSA Class A Common Share Sale $129,445 -7,380 -10% $17.54 66,112 07 Dec 2023 Direct F1, F2
transaction KNSA Class A Common Share Sale $229,620 -13,017 -20% $17.64 53,095 07 Dec 2023 Direct F1, F3
transaction KNSA Class A Common Share Sale $118,960 -6,702 -13% $17.75 46,393 07 Dec 2023 Direct F1, F4
transaction KNSA Class A Common Share Sale $26,733 -1,501 -3.2% $17.81 44,892 07 Dec 2023 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -28,600 -20% $0.000000 111,217 07 Dec 2023 Class A Common Shares 28,600 $1.86 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $17.595. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.60 to $17.695. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.70 to $17.795. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.80 to $17.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F6 The option is fully vested and exercisable.